Cited by 143Renin-Angiotensin System StudiesRenal and Vascular PathologiesChronic Kidney Disease and Diabetes

Angiotensin inhibition in renovascular disease: A population-based cohort study

Hackam, Daniel G., Duong-Hua, Minh L., Mamdani, Muhammad, Li, Ping, Tobe, Sheldon W., Spence, J. David, Garg, Amit X.·2008·American Heart Journal

Abstract

Background Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers effectively reduce blood pressure in patients with renovascular disease (RVD); yet, randomized cardiovascular prevention trials of these drugs typically exclude individuals with this condition.Patients and methods We studied the association of renin-angiotensin system inhibition with prognosis in a population-based cohort comprising 3,570 patients with RVD in Ontario, Canada; slightly more than half (n = 1,857, 53%) were prescribed angiotensin inhibitors. The primary outcome was the composite of death, myocardial infarction, or stroke. Secondary outcomes included individual cardiovascular and renal events.Results Patients receiving angiotensin inhibitors had a significantly lower risk for the primary outcome during follow-up (10.0 vs 13.0 events per 100 patient-years at risk, multivariable adjusted hazard ratio [HR] 0.70, 95% CI 0.59-0.82). In addition, hospitalization for congestive heart failure (HR 0.69, 95% CI 0.53-0.90), chronic dialysis initiation (HR 0.62, 95% CI 0.42-0.92), and mortality (HR 0.56, 95% CI 0.47-0.68) was lower in treated patients. Conversely, patients receiving angiotensin inhibitors were significantly more likely to be hospitalized for acute renal failure during follow-up (HR 1.87, 95% CI 1.05-3.33; 1.2 vs 0.6 events per 100 patient-years at risk).Conclusions These data emphasize the high vascular risk of RVD and suggest that angiotensin inhibitors may improve prognosis in this setting at the expense of acute renal toxicity. If the latter are selected in the management of RVD, renal function parameters should be assiduously followed.

Integrity signals

Registry

Crossref · 10.1016/j.ahj.2008.05.013

Cites

56 of 56 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cites

Flagged first, then by citations

1 of the 57 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Hackam, D. G., Duong-Hua, M. L., Mamdani, M., Li, P., Tobe, S. W., Spence, J. D., & Garg, A. X.
Affiliations
  • Western University (CA)
  • Institute for Clinical Evaluative Sciences (CA)
  • University of Toronto (CA)
Corresponding author
Hackam, Daniel G.
Venue
American Heart Journal
Publisher
Elsevier BV
Published
2008-09
Volume
156
Issue
3
Pages
549-555
ISSN
0002-8703 (ISSN-L)
OpenAlex
W1976834810
Cited by
143
References
57
Citations by year
2026: 3 · 2025: 1 · 2024: 8 · 2023: 7 · 2022: 4 · 2021: 3 · 2020: 3 · 2019: 7 · 2018: 12 · 2017: 6 · 2016: 12 · 2015: 8 · 2014: 16 · 2013: 9 · 2012: 13
FWCI
7.28
Type
journal article
Language
en
Open access
closed
Locations
  • American Heart Journal (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Renal and Vascular Pathologies
  • Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
Keywords
renovascular disease, ACE inhibitors, angiotensin receptor blockers, renin-angiotensin system blockade, cardiovascular outcomes, acute kidney injury, congestive heart failure, dialysis initiation, mortality, stroke, myocardial infarction, renal function monitoring
MeSH terms
Aged, Aged, 80 and over, Angiotensins, Cardiovascular Diseases, Female, Follow-Up Studies, Heart Failure, Renal Dialysis, Hormone Antagonists, Hospitalization, Humans, Kidney, Kidney Diseases, Male, Myocardial Infarction, Renin-Angiotensin System, Vascular Diseases, Cohort Studies, Proportional Hazards Models, Risk Assessment, Stroke, Acute Kidney Injury

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review